News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Amgen Develops Six Cancer Drugs as Anemia Decline Hurts Revenue
April 11, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
April 11 (Bloomberg) -- Amgen Inc., the world's largest biotechnology company by sales, is developing six cancer drugs to help recover from a decline in its anemia products.
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
Amgen
MORE ON THIS TOPIC
Huntington’s disease
Roche scraps 2 Huntington’s studies, handing Ionis more bad news
July 10, 2026
·
2 min read
·
Tristan Manalac
Artificial intelligence
Biopharma R&D needs ‘structural redesign’ to maximize AI impact: report
July 9, 2026
·
2 min read
·
Nick Paul Taylor
Cardiovascular disease
AstraZeneca, Ionis slip as ATTR-CM drug fails Phase 3
July 9, 2026
·
3 min read
·
Tristan Manalac
Podcast
Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil
July 8, 2026
·
1 min read
·
Jef Akst
